The way forward for therapeutics value assessment PolicyBiotech Nov 15 Written By Thomas Culman GCEAhealth economicsRA Capital AuthorCost Effectiveness AnalysisGeneralized Cost Effectiveness Analysis Thomas Culman
The way forward for therapeutics value assessment PolicyBiotech Nov 15 Written By Thomas Culman GCEAhealth economicsRA Capital AuthorCost Effectiveness AnalysisGeneralized Cost Effectiveness Analysis Thomas Culman